JP2022551525A5 - - Google Patents
Info
- Publication number
- JP2022551525A5 JP2022551525A5 JP2022521570A JP2022521570A JP2022551525A5 JP 2022551525 A5 JP2022551525 A5 JP 2022551525A5 JP 2022521570 A JP2022521570 A JP 2022521570A JP 2022521570 A JP2022521570 A JP 2022521570A JP 2022551525 A5 JP2022551525 A5 JP 2022551525A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- approximately
- methoxyurea
- tetrahydrothieno
- difluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913606P | 2019-10-10 | 2019-10-10 | |
| US62/913,606 | 2019-10-10 | ||
| PCT/EP2020/078475 WO2021069700A1 (en) | 2019-10-10 | 2020-10-09 | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551525A JP2022551525A (ja) | 2022-12-09 |
| JP2022551525A5 true JP2022551525A5 (enExample) | 2023-10-17 |
| JP7713934B2 JP7713934B2 (ja) | 2025-07-28 |
Family
ID=72852647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521570A Active JP7713934B2 (ja) | 2019-10-10 | 2020-10-09 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220372044A1 (enExample) |
| EP (1) | EP4041738A1 (enExample) |
| JP (1) | JP7713934B2 (enExample) |
| CN (1) | CN115175912B (enExample) |
| WO (1) | WO2021069700A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| EP4243829A1 (en) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1591446B1 (en) * | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| TWI508962B (zh) * | 2009-04-22 | 2015-11-21 | Du Pont | 氮雜環醯胺之固體形態 |
| KR20190120458A (ko) * | 2010-10-21 | 2019-10-23 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
| US20150099753A1 (en) * | 2012-05-11 | 2015-04-09 | Concert Pharmaceuticals Inc. | Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine |
| PL2900675T3 (pl) * | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| CN110248661A (zh) * | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| EP3518933B2 (en) * | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| WO2019178304A1 (en) * | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| WO2020230094A1 (en) * | 2019-05-15 | 2020-11-19 | Dr. Reddy’S Laboratories Limited | Amorphous and crystalline forms of relugolix |
| CN111423452B (zh) * | 2020-03-26 | 2023-08-22 | 江西青峰药业有限公司 | 瑞卢戈利的中间体及其制备方法和应用 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN115947734A (zh) * | 2021-10-09 | 2023-04-11 | 江苏希迪制药有限公司 | 瑞卢戈利溶剂化物的晶型及其制备方法 |
-
2020
- 2020-10-09 EP EP20790251.1A patent/EP4041738A1/en active Pending
- 2020-10-09 CN CN202080082800.6A patent/CN115175912B/zh active Active
- 2020-10-09 WO PCT/EP2020/078475 patent/WO2021069700A1/en not_active Ceased
- 2020-10-09 JP JP2022521570A patent/JP7713934B2/ja active Active
-
2022
- 2022-04-08 US US17/716,965 patent/US20220372044A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551525A5 (enExample) | ||
| JP5411734B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| AU2008206759B2 (en) | Nicotinic acetylcholine receptor modulators | |
| JP2022551316A5 (enExample) | ||
| JP2022023891A (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
| NL1026438C2 (nl) | Nieuwe verbindingen. | |
| WO2010059922A1 (en) | Pyrrolidine carboxamide compounds | |
| JP2017141274A (ja) | ピロール誘導体の結晶 | |
| JP2024540922A5 (enExample) | ||
| CA2505361A1 (en) | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | |
| CA2194481A1 (en) | 2-ureido-benzamide derivatives | |
| JP2002521377A (ja) | ビフェニル誘導体 | |
| JP2024505063A5 (enExample) | ||
| TW200800211A (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
| JP2019510801A5 (enExample) | ||
| JP2022540922A5 (enExample) | ||
| JP2024514090A5 (enExample) | ||
| JP2002509135A (ja) | 神経細胞カルシウムチャンネルの活性の調節剤としてのアミノスルホニルベンズアミド誘導体 | |
| AU2001248753B2 (en) | Nitrogenous compounds and antiviral drugs containing the same | |
| BRPI0618976A2 (pt) | composto derivado de pirazolisoquinolina, processo para a preparação do mesmo, composição farmacêutica e uso do composto | |
| JPS59167552A (ja) | ベンズアミド誘導体 | |
| JPH04288073A (ja) | ピペラジン誘導体 | |
| WO1997046515A1 (en) | Substituted benzenes having nos inhibitory effects | |
| KR20020019923A (ko) | 벤조일피리다진 |